BRPI0715331B8 - polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo - Google Patents
polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmoInfo
- Publication number
- BRPI0715331B8 BRPI0715331B8 BRPI0715331A BRPI0715331A BRPI0715331B8 BR PI0715331 B8 BRPI0715331 B8 BR PI0715331B8 BR PI0715331 A BRPI0715331 A BR PI0715331A BR PI0715331 A BRPI0715331 A BR PI0715331A BR PI0715331 B8 BRPI0715331 B8 BR PI0715331B8
- Authority
- BR
- Brazil
- Prior art keywords
- terminal portion
- polypeptide
- polypeptides
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
Abstract
derivados de citoquina. a presente invenção refere-se a polipeptídeos que compreendem uma parcela n-terminal e uma parcela c-termina, sendo que cada parcela n-terminal compreende a sequência de assinatura qgp[p ou l] e a seuquência de aminoácido da referida parcela c- terminal é pelo menos 70% idêntica à seq in no: 1, seus empregos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0614755.7A GB0614755D0 (en) | 2006-07-25 | 2006-07-25 | Cytokine derivatives |
| GB0614755.7 | 2006-07-25 | ||
| GB06147557 | 2006-07-25 | ||
| PCT/IB2007/003026 WO2008012689A2 (en) | 2006-07-25 | 2007-07-25 | Cytokine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0715331A2 BRPI0715331A2 (pt) | 2013-07-16 |
| BRPI0715331B1 BRPI0715331B1 (pt) | 2021-04-13 |
| BRPI0715331B8 true BRPI0715331B8 (pt) | 2021-05-25 |
Family
ID=37006114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0715331A BRPI0715331B8 (pt) | 2006-07-25 | 2007-07-25 | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8686111B2 (pt) |
| EP (1) | EP2076532B1 (pt) |
| JP (1) | JP5224603B2 (pt) |
| KR (1) | KR101530353B1 (pt) |
| CN (1) | CN101511867B (pt) |
| AT (1) | ATE490270T1 (pt) |
| AU (1) | AU2007278894B2 (pt) |
| BR (1) | BRPI0715331B8 (pt) |
| CA (1) | CA2658806C (pt) |
| CY (1) | CY1111630T1 (pt) |
| DE (1) | DE602007010969D1 (pt) |
| DK (1) | DK2076532T3 (pt) |
| ES (1) | ES2361455T3 (pt) |
| GB (1) | GB0614755D0 (pt) |
| HK (1) | HK1131162A1 (pt) |
| HR (1) | HRP20110146T1 (pt) |
| ME (1) | ME01320B (pt) |
| MX (1) | MX2009000918A (pt) |
| NZ (1) | NZ575092A (pt) |
| PL (1) | PL2076532T3 (pt) |
| PT (1) | PT2076532E (pt) |
| RS (1) | RS51854B (pt) |
| RU (1) | RU2461567C2 (pt) |
| SI (1) | SI2076532T1 (pt) |
| WO (1) | WO2008012689A2 (pt) |
| ZA (1) | ZA200901342B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600091033A1 (it) * | 2016-09-08 | 2018-03-08 | Bioimmunizer Sagl | Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti. |
| MX2020012782A (es) * | 2018-05-28 | 2021-04-28 | ORION Biotechnology Switzerland Sarl | Inhibidor de ccr5 para el uso en el tratamiento de cancer. |
| CA3101052A1 (en) * | 2018-05-28 | 2019-12-05 | ORION Biotechnology Switzerland Sarl | Methods of inhibiting cerebral inflammation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9406821A (pt) * | 1993-06-09 | 1996-03-26 | Connaught Lab | Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo |
| FR2748938B1 (fr) | 1996-05-22 | 1998-07-31 | Pasteur Institut | Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih |
| UA77950C2 (en) | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| US20030049603A1 (en) | 2001-09-05 | 2003-03-13 | Guy Gorochov | Methods for construction and screening of libraries of chemokine variants |
| US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| WO2005112567A2 (en) | 2004-05-03 | 2005-12-01 | University Of Maryland Biotechnology Institute | Vaginal microbicide |
-
2006
- 2006-07-25 GB GBGB0614755.7A patent/GB0614755D0/en not_active Ceased
-
2007
- 2007-07-25 JP JP2009521377A patent/JP5224603B2/ja active Active
- 2007-07-25 ES ES07825334T patent/ES2361455T3/es active Active
- 2007-07-25 PL PL07825334T patent/PL2076532T3/pl unknown
- 2007-07-25 SI SI200730500T patent/SI2076532T1/sl unknown
- 2007-07-25 AT AT07825334T patent/ATE490270T1/de active
- 2007-07-25 EP EP07825334A patent/EP2076532B1/en active Active
- 2007-07-25 NZ NZ575092A patent/NZ575092A/en not_active IP Right Cessation
- 2007-07-25 RU RU2009106436/10A patent/RU2461567C2/ru active
- 2007-07-25 CN CN200780032719.1A patent/CN101511867B/zh active Active
- 2007-07-25 BR BRPI0715331A patent/BRPI0715331B8/pt active IP Right Grant
- 2007-07-25 MX MX2009000918A patent/MX2009000918A/es active IP Right Grant
- 2007-07-25 AU AU2007278894A patent/AU2007278894B2/en active Active
- 2007-07-25 CA CA2658806A patent/CA2658806C/en active Active
- 2007-07-25 DK DK07825334.1T patent/DK2076532T3/da active
- 2007-07-25 PT PT07825334T patent/PT2076532E/pt unknown
- 2007-07-25 KR KR1020097003947A patent/KR101530353B1/ko active IP Right Grant
- 2007-07-25 DE DE602007010969T patent/DE602007010969D1/de active Active
- 2007-07-25 RS RS20110103A patent/RS51854B/en unknown
- 2007-07-25 ME MEP-2011-47A patent/ME01320B/me unknown
- 2007-07-25 WO PCT/IB2007/003026 patent/WO2008012689A2/en active Application Filing
- 2007-07-25 US US12/309,569 patent/US8686111B2/en active Active
-
2009
- 2009-02-24 ZA ZA2009/01342A patent/ZA200901342B/en unknown
- 2009-10-15 HK HK09109545.2A patent/HK1131162A1/xx unknown
-
2011
- 2011-02-23 CY CY20111100216T patent/CY1111630T1/el unknown
- 2011-02-28 HR HR20110146T patent/HRP20110146T1/hr unknown
-
2013
- 2013-06-04 US US13/909,845 patent/US9328153B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS53505B1 (en) | OXYTOMODULIN PEPTIDE ANALOG | |
| NO20063026L (no) | Antistoffer | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| IN2014CN02050A (pt) | ||
| NZ600690A (en) | Fkbp-l and uses thereof | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| GEP20115196B (en) | Neublastin variants | |
| NZ609216A (en) | Anticancer fusion protein | |
| HK1088613A1 (en) | Peptide inhibitors of toxins derived from ll-37 | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| WO2006097432A3 (de) | Keratin-biktdende desmoplakinpolypeptidsequenzen | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| BRPI0508916A (pt) | polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os | |
| NZ601647A (en) | Variant hhip1 protein and methods and uses thereof | |
| DK1913020T3 (da) | Immunogene konstrukter | |
| ES2557938T3 (es) | Antagonistas de resistina y su uso | |
| ATE441865T1 (de) | Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila | |
| NZ570708A (en) | Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof | |
| ES2421885T3 (es) | Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia | |
| SG170757A1 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
| DE602007006493D1 (de) | Peptide mit proliferationshemmender wirkung | |
| DE602007011202D1 (de) | Peptid zur hemmung von calcineurin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MINTAKA FOUNDATION FOR MEDICAL RESEARCH (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ORION BIOTECHNOLOGY SWITZERLAND SARL (CH) |
|
| B25G | Requested change of headquarter approved |
Owner name: ORION BIOTECHNOLOGY SWITZERLAND SARL (CH) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |